The Hypothesis

I propose that the DNA methylation changes seen at ANK1, RHBDF2, and CDH23 in people before symptoms appear aren't just associated with Alzheimer's pathology—they actually drive the disease forward. Specifically, these epigenetic changes silence genes that regulate copper, which are critical for keeping mitochondria functioning and maintaining Aβ balance. The result is a vicious cycle: as copper chaperones (especially CCS and ATOX1) get shut down, the brain ramps up Aβ production as a desperate way to grab onto copper. Eventually this system hits a wall and collapses.

The Mechanistic Basis

Aβ can chelate toxic metals through its histidine residues, and BACE1 gets upregulated via NF-κB inflammatory signaling triggered by oxidative damage. But we still don't fully understand what's causing that persistent ROS generation in the first place. Copper dyshomeostasis seems to tie everything together—mitochondrial copper is required for cytochrome c oxidase (Complex IV), and when it's depleted, the electron transport chain malfunctions, ROS floods the system, and neuroinflammation follows.

What This Predicts

If ANK1 methylation really does suppress copper chaperone expression in neurons, we'd expect to see: (1) reduced neuronal copper despite normal copper levels elsewhere in the body, (2) Aβ going up as a backup copper-binding strategy, (3) problems that get worse with age as chaperone capacity fades, and (4) patients responding to treatment that combines HDAC inhibitors with copper supplementation—rebuilding chaperone expression while actually providing the copper the brain needs. This is the opposite of simple chelation approaches, which strip copper out.

How to Test It

This hypothesis makes predictions we can actually measure: imaging copper in patient-derived neurons that have ANK1 hypermethylation, measuring CCS and ATOX1 expression in epigenome-wide association studies, and running trials that compare HDAC inhibitors plus copper against either treatment alone.

Why This Builds on Existing Work

Prior research showed that epigenetic changes explain more variance than APOE and appear before amyloid pathology shows up. But nobody specified which downstream pathways get silenced. By pointing to copper chaperone suppression as the direct molecular trigger, this turns a biomarker correlation into something we can actually act on mechanistically—explaining the whole sequence from DNA methylation to metal dysregulation to amyloid overcompensation to system failure.